Work

NK cell recovery after CD19.CAR-T cell therapy in systemic sclerosis with pulmonary fibrosis: A case study

Year: 2024

Type: conference-paper

Abstract: Introduction: Standard therapy of Systemic Sclerosis (SSc)-associated interstitial lung disease (ILD) can not cure, but only decelerate disease progression. CD19-targeting CAR-T cells have the potential to revolutionize anti-rheumatic therapies by eliminating autoantibodies, yet their effects on downstream [for full text, please go to the a.m. URL]

Source: German Medical Science (German Research Foundation)

DOI: 10.3205/24dgrh023

Authors: Claus, Maren, Freitag, Merle, Rodon, Lea, Deicher, Franca, Watzl, Carsten, Lorenz, Hanns-Martin, Schmitt, Michael, Merkt, Wolfgang

Institutions: TU Dortmund University, Leibniz Research Centre for Working Environment and Human Factors, Heidelberg University, University Hospital Heidelberg, Düsseldorf University Hospital

Language: English

Topic: Systemic Sclerosis and Related Diseases

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W6889958335

FWCI:

Cites:

Cited by:

Related to: